Colorectal polyposis and immune-based therapies

Canadian Journal of Gastroenterology

Volumn 18, Issue 4, 2004, Pages 239-249

  Jacobson Brown, Pearl ^a   Neuman, Manuela G ^a,b  

^a Kunin Lunenfeld Applied Research Unit and Department of Food and Nutrition Services and Baycrest Centre for Geriatric Care   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adenomatous polyps; Angiogenic; Antibody cytokine fusion proteins; Apptosis; Colorectal cancer; Cytokines; Integrin

Indexed keywords

ACETYLSALICYLIC ACID; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; BETA INTERFERON; BEVACIZUMAB; CD8 ANTIGEN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; ROFECOXIB; SOMATOMEDIN; SULINDAC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CELL ADHESION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CARCINOGENESIS; COLON POLYPOSIS; COLORECTAL CANCER; CROHN DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; INTESTINE PERFORATION; KIDNEY DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; RAT; RECTUM POLYP; REVIEW; T LYMPHOCYTE ACTIVATION; TREATMENT PLANNING; TUMOR GROWTH; TUMOR IMMUNITY; ULCERATIVE COLITIS; VASCULAR DISEASE; VIRAL GENE THERAPY;

EID: 2342516209     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/742713     Document Type: Review

References (134)

1. Brunagel G, Schoen RE, Getzenberg RH. Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps. J Cell Biochem 2004;91:365-74.
2. Ellis LM, Ahmad S, Fan F, et al. Angiopoietins and their role in colon cancer angiogenesis. Oncology 2002;16(Suppl 3):31-5.
3. Compton CC. Colorectal carcinoma: Diagnostic, prognostic, and molecular features. Mod Pathol 2003;16:376-88.
4. Adegboyega PA, Mifflin RC, DiMari JF, et al. Immunohistochemical study of myofibroblasts in normal colonic mucosa, hyperplastic polyps, and adenomatous colorectal polyps. Arch Pathol Lab Med 2002;126:829-36.
5. Dohlsten M, Lando PA, Bjork P, et al. Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother 1995;41:162-8.
6. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
7. Makrigiannis AP, Musgrave BL, Mansour H, et al. Interleukin-12 can replace CD28-dependent T-cell costimulation during nonspecific cytotoxic T lymphocyte induction by anti-CD3 antibody. J Leukoc Biol 2001;69:113-22.
8. Maraskovsky E, Chen WF, Shortman K. IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J Immunol 1989;143:1210-4.
9. Siapati KE, Barker S, Kinnon C, et al. Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12. Br J Cancer 2003;88:1641-8.
10. Tanaka M, Saijo Y, Sato G, et al. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma. Cancer Gene Ther 2000;7:1481-90.
11. Smyth MJ, Takeda K, Hayakawa Y, et al. Nature's TRAIL - on a path to cancer immunotherapy. Immunity 2003;18:1-6.
12. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
13. Chen G, Goeddel DV. TNF-R1 signaling: A beautiful pathway. Science 2002;296:1634-5.
14. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: Molecular mechanisms. J Pathol 2003;199:275-88.
15. Walczak H, Miller RE, Ariali K, et al. Tumoricidal activity of tumour-necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999;5:157-63.
16. Teicher BA. Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer Metastasis Rev 2001;20:133-43.
17. Guda K, Giardina C, Nambiar P, et al. Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors. Mol Carcinog 2001;31:204-13.
18. Dimberg J, Hugander A, Sirsjo A. Decreased levels of precursor transforming growth factor beta1 in human colorectal cancer. Int J Mol Med 2001;7:597-601.
19. Thomas GJ, Hart IR, Speight PM, et al. Binding of TGF-beta 1 latency-associated peptide (LAP) to alpha(v)beta6 integrin modulates behaviour of squamous carcinoma cells. Br J Cancer 2002;87:859-67.
20. Torbenson M, Marinopoulos S, Dang DT, et al. Smad4 overexpression in hepatocellular carcinoma is strongly associated with transforming growth factor beta II receptor immunolabeling. Hum Pathol 2002;33:871-6.
21. Kushiyama Y, Fukuda R, Suetsugu H, et al. Site-dependent production of transforming growth factor beta1 in colonic mucosa: Its possible role in tumorigenesis of the colon. J Lab Clin Med 2000;136:201-8.
22. Kelly-Welch AE, Hanson EM, Boothby MR, et al. Interleukin-4 and interleukin-13 signaling connections maps. Science 2003;300:1527-8.
23. Anasagasti MJ, Olaso E, Calvo F, et al. Interleukin 1-dependent and -independent mouse melanoma metastases. J Natl Cancer Inst 1997;89:645-51.
24. Mansoor A, Hoosein N. Relationship of the interleukin-1 system with neuroendocrine and exocrine markers in human colon cancer cell lines. Cytokine 2002;18:86-91.
25. Brew R, Erikson JS, West DC, et al. Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 2000;12:78-85.
26. Bonecchi R, Facchetti F, Dusi S, et al. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes. J Immunol 20001;164:3862-9.
27. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
28. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001;7:3971-6.
29. Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002;21:193-201.
30. Rocca B, Spain LM, Pure E, et al. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. J Clin Invest 1999;103:1469-77.
31. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
32. Dormand O, Ruegg C. Inhibition of tumor angiogenesis by non-streroidal anti-inflammatory drugs: Emerging mechanisms and therapeutic perspectives. Drug Resist Updat 2001;4:314-21.
33. Jacobson-Brown P, Neuman MG. Colon polyps and cytokines: Emerging immunological mechanisms. Rom J Gastroenterol 2003;12:207-14.
34. Kwak JY, Han MK, Chaoi KS, et al. Cytokines secreted by lymphokine-activated killer cells induce endogenous nitric oxide synthesis and apoptosis in DLD-1 colon cancer cells. Cell Immunol 2000;203:84-94.
35. Pellegrini P, Berghella AM, Del Beato T, et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996;42:1-8.
36. Wang YQ, Ugai S, Shimozato O, et al. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 2003;105:820-4.
37. Luo JS, Kammerer R, Schultze H, et al. Modulations of the effector function and cytokine production of human lymphocytes by secreted factors derived from colorectal-carcinoma cells. Int J Cancer 1997;72:142-8.
38. Kornberg LJ. Focal adhesion kinase and its potential involvement in tumor invasion and metastasis. Head Neck 1998;20:745-52.
39. Hague A, Hicks DJ, Bracey TS, et al. Cell-cell contact and specific cytokines inhibit apoptosis of colonic epithelial cells: Growth factors protect against c-myc-independent apoptosis. Br J Cancer 1997;75:960-8.
40. Sun FF, Lai PS, Yue G, et al. Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat. Inflammation 2001;25:33-41.
41. Melero I, Gabari I, Corbi AL, et al. An anti-ICAM-2 (CD102) monoclonal antibody induces immune-mediated regressions of transplanted ICAM-2-negative colon carcinomas. Cancer Res 2002;62:3167-74.
42. Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003;22:359-74.
43. Walsh MF, Thamilselvan V, Grotelueschen R, et al. Absence of adhesion triggers differential FAK and SAPKp38 signals in SW620 human colon cancer cells that may inhibit adhesiveness and lead to cell death. Cell Physiol Biochem 2003;13:135-46.
44. Avizienyte E, Wyke AW, Jones RJ, et al. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol 2002;4:632-8.
45. Kanai T, Watanabe M, Hayashi A, et al. Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br J Cancer 2000;82:1717-23.
46. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000;157:1415-30.
47. Osaki M, Kase S, Kodani I, et al. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: Correlation with proliferation and apoptosis. Gastric Cancer 2001;4:198-205.
48. Belluco C, Esposito G, Bertorelle R, et al. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol 2002;28:120-5.
49. Herbeuval JP, Lambert C, Sabido O, et al. Macrophages from cancer patients: Analysis of TRAIL, TRAIL receptors, and colon tumor cell apoptosis. J Natl Cancer Inst 2003;95:611-21.
50. Dong M, Guda K, Nambiar PR, et al. Inverse association between phospholipase A2 and COX-2 expression during mouse colon tumorigenesis. Carcinogenesis 2003;24:307-15.
51. Shibata M, Takekawa M, Amano S. Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer. Surg Today 1998;28:884-8.
52. Iwagaki H, Yagi T, Urushihara N, et al. Blood transfusion and postoperative plasma cytokine antagonist levels in colorectal cancer patients. Hepatogastroenterology 2001;48:1351-4.
53. Fink SP, Swinler SE, Lutterbaugh JD, et al. Transforming growth factor-beta-induced growth inhibition in a Smad4 mutant colon adenoma cell line. Cancer Res 2001;61:256-60.
54. Fukushima T, Mashiko M, Takita K, et al. Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer. J Exp Clin Cancer Res 2003;22:315-20.
55. Matsushita M, Matsuzaki K, Date M, et al. Down-regulation of TGF-beta receptors in human colorectal cancer: Implications for cancer development. Br J Cancer 1999;80:194-205.
56. Strassmann G, Fong M, Windsor S, et al. The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 1993;5:285-90.
57. Kojima M, Morisaki T, Izuhara K, et al. Lipopolysaccharide increases cyclo-oygenase-2 expression in a colon carcinoma cell line through nuclear factor-kappa B activation. Oncogene 2000;19:1225-31.
58. McKelvey W, Greenland S, Sandler RS. A second look at the relation between colorectal adenomas and consumption of foods containing partially hydrogenated oils. Epidemiology 2000;11:469-73.
59. Erhardt JG, Kreichgauer HP, Meisner C, et al. Alcohol, cigarette smoking, dietary factors and the risk of colorectal adenomas and hyperplastic polyps - a case control study. Eur J Nutr 2002;41:35-43.
60. Mutanen M, Pajari AM, Oikarinen SI. Beef induces and rye bran prevents the formation of intestinal polyps in Apc(Min) mice: Relation to beta-catenin and PKC isozymes. Carcinogenesis 2000;21:1167-73.
61. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002;94:972-80.
62. Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002;8:3259-69.
63. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001;131:3109S-20S.
64. Remacle-Bonnet MM, Garrouste FL, Heller S, et al. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 2000;60:2007-17.
65. Buttar NS, Wang KK. The "aspirin" of the new millennium: Cyclooxygenase-2 inhibitors. Mayo Clin Proc 2000;75:1027-38.
66. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
67. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
68. Takafuji V, Lublin D, Lynch K, et al. Mucosal prostanoid receptors and synthesis in familial adenomatous polyposis. Histochem Cell Biol 2001;116:171-81.
69. Sonoshita M, Takaku K, Sasaki N, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med 2001;7:1048-51.
70. Oshima M, Murai N, Kargman S, et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001;61:1733-40.
71. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-36.
72. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575-89.
73. Gustafson-Svard C, Lilja I, Hallbook O, et al. Cyclo-oxygenase and colon cancer: Clues to the aspirin effect? Ann Med 1997;29:247-52.
74. Muller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer. A case-control study among veterans. Dig Dis Sci 1994;39:2480-4.
75. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
76. Cryer B. The role of cyclooxygenase selective inhibitors in the gastrointestinal tract. Curr Gastroenterol Rep 2003;5:453-8.
77. Peura DA. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med 2002;69(Supp 1):SI31-9.
78. Deviere J. Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy? Eur J Gastroenterol Hepatol 2002;14(Suppl 1):S29-33.
79. Weir MR, Sperling RS, Reicin A, et al. Selective COX-2 inhibition and cardiovascular effects: A review of the rofecoxib development program. Am Heart J 2003;146:591-604.
80. Netea MG, Puren AJ, Dinarello CA. A short course of oral aspirin increases IL-18-induced interferon-gamma production in whole blood cultures. Eur Cytokine Netw 2000;11:379-82.
81. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
82. Torres C, Antonioli D, Odze RD. Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up Study of 89 polyps from 59 patients. Am J Surg Pathol 1998;22:275-84.
83. Chawla A, Judge TA, Lichtenstein GR. Evaluation of polypoid lesions in inflammatory bowel disease. Gastrointest Endosc Clin N Am 2002;12:525-34,ix.
84. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumour necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
85. Fogt F. Sporadic adenomas in chronic ulcerative colitis. Z Gastroenterol 2003;41:343-6.
86. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann Rev Med 2000;51:289-98.
87. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.
88. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: A randomised controlled trial. Gut 2003;52:998-1002.
89. Hanauer SB, Lichtenstein GR, Colombel JF, et al. Maintenance infliximab (Remicade®) is safe, effective and steroid-sparing in Crohn's disease: Preliminary results from the Accent I trial. Gastroenterology 2001;120(Supp 1):99.
90. Su CG, Lichtenstein GR. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Gastroenterology 2003;125:1544-6.
91. Papadakis KA, Treyzon L, Abreu MT, et al. Infliximab in the treatment of medically refractory indeterminate colitis. Aliment Pharmacol Ther 2003;18:741-7.
92. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11.
93. Van Deventer SJH. Targeting TNF-α as a key cytokine in the inflammatory processes of Crohn's disease the mechanism of action of infliximab. Aliment Pharmacol Ther 1999;13(Suppl):43-8.
94. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001;15:212:22.
95. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Path 1997;151:97-110.
96. Napier J, Wong RK. Natalizumab: A new hope for Crohn's disease? Am J Gastroenterol 2003;98:1197-9.
97. Ghosh S. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease: The role of natalizumab. Expert Opin Biol Ther 2003;3:995-1000.
98. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32.
99. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002;16:699-705.
100. Gordon F, Lai CWY, Hamilton MI, et al. Randomized double-blinded placebo-controlled trial of recombinant humanized antibody to alpha-4 integrin (Antegren) in active Crohn's disease. Gastroenterology 2001;121:268-74.
101. Antegren Publication Committee. A randomised, double-blind, placebo-controlled, Pan-European Study of a recombinant humanised antibdy to 4 Integrin (Antegren™) in moderate to severely active Crohn's disease. Gastroenterology 2001;120(Suppl 1):682.
102. Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut 1995;36:724-30.
103. Rutgeerts P, Van Deventer S, Schreiber S. The expanding role of biological agents in the treatment of inflammatory bowel disease - focus on selective adhesion molecule inhibition. Aliment Pharm Ther 2003;17:1435-46.
104. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003;30(Suppl 6):39-50.
105. Jain RK. Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor. Semin Oncol 2002;29(Suppl 16):3-9.
106. Ellis LM. A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am Surg 2003;69:3-10.
107. Willett CG, Boucher Y, Di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
108. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
109. Salgaller ML. Technology evaluation: Bevacizumab, Genentech/Roche. Curr Opin Mol Ther 2003;5:657-67.
110. Zwacka RM, Dunlop MG. Gene therapy for colon cancer. Hematol Oncol Clin North Am 1998;12:595-615.
111. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: Targeting and replication competent viral vectors. Crit Rev Oncol Hematol 2001;38:177-92.
112. Lichtor T, Glick RP. Cytokine immuno-gene therapy for treatment of brain tumors. J Neurooncol 2003;65:247-59.
113. Chada S, Ramesh R, Mhashilkar AM. Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 2003;5:463-74.
114. Tamura T, Nishi T, Goto T, et al. Combination of IL-12 and IL-18 of electro-gene therapy synergistically inhibits tumor growth. Anticancer Res 2003;23(2B):1173-9.
115. Wang Z, Qiu SJ, Ye SL, et al. Combine IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma. Cancer Gene Ther 2001;8:751-8.
116. Palmer DH, Chen MJ, Kerr DJ. Gene therapy for colorectal cancer. Br Med Bull 2002;64:201-25.
117. Stingl G, Brocker EB, Mertelsmann R, et al. Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. Hum Gene Ther 1996;7:551-63.
118. Mazzolini G, Qian C, Xie X, et al. Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12. Hum Gene Ther 2000;11:1851-62.
119. Pham-Nguyen KB, Yang W, Saxena R, et al. Role of NK and T cells in IL-12-induced anti-tumor response against hepatic colon carcinoma. Cancer Gene Ther 1999;6:514-22.
120. Mendiratta SK, Quezada A, Matar M, et al. Combination of interleukin-12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma. Clin Cancer Res 2002;8:2488-98.
121. Eguchi J, Hiroishi K, Ishii S, et al. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing. Cancer Immunol Immunother 2003;52:378-86.
122. Kobayashi N, Kuramoto T, Chen S, et al. Therapeutic effect of intravenous interferon gene delivery with naked plasmid DNA in murine metastasis models. Mol Ther 2002;6:737-44.
123. Niv Y, Koren R. Modulation of mucin synthesis by gamma-interferon in human colon adenocarcinoma cells. Digestion 2003;67:50-5.
124. Schwartzberg LS, Petak I, Stewart C, et al. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: Phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin. Clin Cancer Res 2002;8:2488-98.
125. Tada H, Maron DJ, Choi EA, et al. Systemic IFN-beta gene therapy results in long-term survival in mice with established colorectal liver metastases. J Clin Invest 2001;108:83-95.
126. Kase S, Kubota T, Watanabe M, et al. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Anticancer Res 1993;13:369-73.
127. Odaka M, Wiewrodt R, DeLong P, et al. Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy. Mol Ther 2002;6:210-8.
128. Penichet ML, Morrison SL. Antibody-cytokine fusion proteins for the therapy of cancer. J Immunol Methods 2001;248:91-101.
129. Becker JC, Varki N, Gillies SD, et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci U S A 1996;93:7826-31.
130. Lode HN, Xiang R, Duncan SR, et al. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12. Proc Natl Acad Sci USA 1999;96:8591-6.
131. Sondel PM, Hank JA. Antibody-directed, effector cell-mediated tumor destruction. Hematol Oncol Clin North Am 2001;15:703-21.
132. Lustgarten J, Marks J, Sherman LA. Redirecting effector T cells through their IL-2 receptors. J Immunol 1999;162:359-65.
133. Xiang R, Lode HN, Dolman CS, et al. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res 1997;57:4948-55.
134. Xiang R, Lode HN, Gillies SD, et al. T cell memory against colon carcinoma is long-lived in the absence of antigen. J Immunol 1999;163:3676-83.